← All companies

Asymchem

3 reports

Research on this company

Bernstein

Bernstein: Asymchem’s small-molecule business recovers in the third quarter as emerging-business slowdown raises pressure on fourth-quarter deliveries

Third-quarter revenue and core operating profit both fell short of market consensus, while net profit attributable to shareholders exceeded expectations mainly because of non-recurring gains. The company maintained its full-year growth guidance, implying a significant jump in fourth-quarter revenue from the third quarter.

Morgan Stanley

Morgan Stanley: Asymchem: Third-quarter profit beats Morgan Stanley expectations; full-year growth hinges on fourth-quarter deliveries

Asymchem’s third-quarter revenue fell short of Morgan Stanley’s expectations, while profit exceeded them, but growth in profit excluding non-recurring items was markedly slower than net profit growth. The company maintained its full-year revenue growth guidance of 19%–22%; concentrated deliveries in its macromolecule businesses and delayed small-molecule projects are key.

Goldman Sachs

Goldman Sachs: Asymchem: Third-quarter deliveries weigh on revenue; fourth-quarter execution and peptide ramp-up are key

Third-quarter revenue fell short of Goldman Sachs’ expectations, while cost controls supported profit. Full-year growth guidance remains unchanged, but delivery pressure has shifted to the fourth quarter. Goldman Sachs remains optimistic that the peptide business will accelerate growth in 2027, while cutting its earnings forecasts and target prices.